These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 22776635)

  • 1. Antipsychotic dosing: extended, and transient.
    Seeman P; Remington G
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):86-7. PubMed ID: 22776635
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical guidelines: Dosing and switching strategies for long-acting risperidone.
    Marder SR; Conley R; Ereshefsky L; Kane JM; Turner MS
    J Clin Psychiatry; 2003; 64 Suppl 16():41-6. PubMed ID: 14680418
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
    Agid O; Foussias G; Remington G
    Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of long-acting risperidone.
    Parker G
    Psychiatr Serv; 2005 Jan; 56(1):105-6; author reply 106-7. PubMed ID: 15637203
    [No Abstract]   [Full Text] [Related]  

  • 5. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antipsychotic medication in the treatment of schizophrenia.
    Kane JM
    Isr J Psychiatry Relat Sci; 1995; 32(1):30-7. PubMed ID: 7542642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Administration of once-daily extended release quetiapine in schizophrenic disorders].
    Bartkó G
    Neuropsychopharmacol Hung; 2007 Dec; 9(4):189-95. PubMed ID: 18510263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Fluspirilene--safe weekly tranquilizer?].
    Kuhn W; Wöhrle M; Müller T; Welter F
    Nervenarzt; 1997 Jun; 68(6):528. PubMed ID: 9312689
    [No Abstract]   [Full Text] [Related]  

  • 9. [Depot antipsychotics in the year 2011].
    Knegtering H; Oolders H; Ruijsink MA; van der Moolen AE
    Tijdschr Psychiatr; 2011; 53(2):95-105. PubMed ID: 21319066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic strategies in schizophrenia.
    Am J Psychiatry; 1988 Jul; 145(7):900-2. PubMed ID: 2898215
    [No Abstract]   [Full Text] [Related]  

  • 11. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses.
    Turner MS; Stewart DW
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Foreword].
    Guelfi JD; Costentin J; Terra JL
    Encephale; 2009 Jan; Suppl 3():S85-6. PubMed ID: 19268183
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose loading with extended release quetiapine.
    Chae BJ
    J Clin Pharm Ther; 2010 Aug; 35(4):487-9. PubMed ID: 20831551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substance abuse and the management of medication nonadherence in schizophrenia.
    Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
    J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expert opinion on APAP (Prolonged action atypical antipsychotic agents). Conclusion].
    Guelfi JD
    Encephale; 2009 Jan; Suppl 3():S123-4. PubMed ID: 19268182
    [No Abstract]   [Full Text] [Related]  

  • 16. What works in schizophrenia: depot preparations may improve outcomes.
    Haddad PM; Niaz O
    BMJ; 2006 Aug; 333(7563):353. PubMed ID: 16902223
    [No Abstract]   [Full Text] [Related]  

  • 17. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 19. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Position of the pharmacologist. From neuroleptics to non-neuroleptic antipsychotics].
    Costentin J
    Encephale; 2009 Jan; Suppl 3():S119-22. PubMed ID: 19268181
    [No Abstract]   [Full Text] [Related]  

  • 20. Risperidone vs. placebo for schizophrenia.
    Kripke C
    Am Fam Physician; 2010 May; 81(9):1096. PubMed ID: 20433125
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.